Back to STAA
STAAR Surgical Reports First Quarter 2012 Financial Results

MONROVIA, Calif., May 2, 2012 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that sales of its Visian ICL product in the first quarter ended March 30, 2012 increased 25% to $8.6 million. Total revenue grew 4% to $15.5 million from $14.8 million in the first quarter of 2011. Gross margin set another quarterly record at 70.3%, 550 basis points above the 64.8% margin in the first quarter of 2011 and 50 basis points above the 69.8% margin in the fourth quarter of 2011. This was the highest gross margin since 1998 and represented the sixth consecutive quarterly gross margin increase. The gross margin improvement continues to reflect the increased contribution of Visian ICL sales and margin improvement in IOLs.

Net income, calculated in accordance with GAAP, was $232,000, or $0.01 per diluted share, compared with net income of $300,000, also $0.01 per diluted share, in the first quarter of 2011. This marked the fifth consecutive quarter of profitability for the Company. Adjusted net income (excluding manufacturing consolidation expenses, gain on foreign currency transactions, fair value adjustment of warrants, and non-cash share-based compensation expense) for the quarter ended March 30, 2012 was $1.4 million, or $0.04 per diluted share. Adjusted net income for the year ago quarter was $313,000, or $0.01 per diluted share. Cash and cash equivalents at March 30, 2012 totaled $16.4 million.

"We continued to make good progress in our business during the first quarter evidenced by our 30% increase of ICL revenues in our top 11 targeted markets," said Barry G. Caldwell, President and CEO. "This increase in ICL sales combined with our product cost improvements led to significant year over year expansion in gross margin. Our IOL sales were not as strong as expected but we understand why and expect growth for the remainder of the year. Our key metrics are developed on an annualized basis and our first quarter is always the most challenging when compared to our annualized targets. The 2012 start is very similar to the start of 2011 when we missed two of our metrics in the first quarter; only to exceed them as the year progressed. We remain confident that we will achieve our metrics for 2012 which include ICL revenue growth in excess of 32% and total revenue growth of 15%."

"We continue to make progress in the roll-out of the V4c ICL in markets where approved," added Mr. Caldwell. "Our participation at recent ophthalmology conferences in the Middle East and U.S. has confirmed the growing interest in Visian ICL as a true competitor to both standard and customized LASIK with significant patient benefits including improved vision, comfort and safety. The V4c ICL with CentraFLOW technology is gaining traction in Europe and represented 58% of total European ICL sales in the quarter. Surgeons in Europe have already implanted over 1,000 V4c ICLs and the AquaPORT(TM) has performed as expected in all cases. This data further proves the CentraFLOW technology eliminates the need for an iridotomy prior to surgery making the procedure much more convenient and less complicated for both the surgeon and patient."

"We reached another key milestone in gross profit margin expansion by achieving a 70.3% gross margin for the first quarter, our highest margin in 14 years," Mr. Caldwell continued. "Our increased gross margin was due largely to the improved mix toward higher margin ICL sales and improved costs. ICL gross margin for the quarter was 85%, while our IOL margin continued to expand to 60% during the quarter. We expect continued margin improvement during the year due to increased ICL sales and further market penetration of the V4c version."

"Our operating income in the first quarter increased 34% compared with the first quarter of 2011. We continued execution on our plan to consolidate manufacturing and recorded approximately $0.6 million in expenses for that effort in the first quarter. Net income for the recent quarter of $0.2 million was below last year's $0.3 million, attributable to the increase in manufacturing consolidation expenses and the $0.3 million lower gain on foreign currency transactions. Looking ahead, we expect enhanced growth in sales of Visian ICL and total revenue based on the ramp of our newly approved product introductions, expanded awareness of the benefits of our technology and the improvements we continue to make in our operations. We expect to meet all of the key metrics we established earlier this year for the full year 2012," Mr. Caldwell concluded.

2012 Key Metrics

The Company reaffirmed its key target metrics for 2012:

    1. Increase in revenues of 15%.
    2. Exceed the 2011 Visian ICL revenue growth rate of 32%.
    3. Continuous expansion of gross margins to achieve 71% for the full year.
    4. Profitable each quarter and for the full year.
    5. Implement manufacturing consolidation with no disruption to customer
       supply requirements.  This metric will be measured by the amount of
       customer backorders.

Recent Visian Implantable Collamer® Lens (ICL) Highlights

    --  First quarter Visian ICL sales grew to $8.6 million, a 25% increase from
        $6.9 million in the first quarter of 2011.
    --  Sales in STAAR's top 11 targeted markets increased 30% in the first
        quarter.  Asia/Pacific sales grew 50% in the first quarter.  Leading the
        growth were China, up 110%; Japan up 93%; India, up 47%; and Korea, up
        37%.
    --  Sales in EMEA grew an unusually slow 2% in the quarter, primarily due to
        three factors.  First, during March 2011 the Company had two
        distributors stocking the expanded range for the V4b which had just been
        introduced.  With this introduction there were new powers which needed
        to be placed into their inventories.  Secondly, the WOC held in February
        slowed refractive surgery particularly in the Mideast.  This meeting was
        not held in 2011.  Finally, the Company had two fairly large ICL orders
        which were delayed at quarter end due to some logistics issues.
    --  58% of total ICL sales to European markets during the first quarter of
        2012 were of the Visian V4c ICL.  There have been over 1,000 implants of
        the V4c in Europe with the AquaPORT performing as expected in all cases.
    --  ICL sales in North America increased by 4% during the quarter.  U.S. ICL
        sales in the first quarter grew 2%.  Sales to private sector accounts
        increased by 6% while military sales of ICLs during the quarter
        decreased 34% from the prior year due to key ICL surgeon deployment or
        retirement.  The Company expects to see an improvement in military ICL
        sales during the second half of 2012.

Recent Intraocular Lens (IOL) Highlights

    --  First quarter IOL sales decreased 11% or $0.8 million to $6.4 million
        compared with $7.1 million in the first quarter of 2011.
    --  During the first quarter of 2011 the Company transitioned the business
        in Australia from a direct distribution model to an indirect model.  In
        that transition it sold its inventory to the new distributor creating a
        revenue comparison for the quarter unrelated to actual demand.  That
        negative impact for comparative purposes was over $0.4 million or
        approximately half of the quarter over quarter decline.
    --  Preloaded IOLs in Japan declined by 7% or $0.2 million.  Key factors
        were aggressive competitive pricing during the quarter though the
        Company's price actually increased by 2%.  Finalizing the KS-SP
        preloaded single piece acrylic IOL is important for that market.  The
        Company believes it has now solved the technical issues regarding
        delivery of the lens.  A focus remains on gaining incremental university
        accounts where the average prices are higher.  During the month of April
        the Company saw a return to IOL revenue growth in Japan.
    --  In the U.S., silicone IOL sales decreased nearly $0.3 million.  Sales of
        nanoFLEX and Silicone Toric IOLs did not outpace the loss in standard
        silicone lenses.
    --  IOL gross margins improved by 200 basis points to 60% for the quarter. 
        Cost improved reflecting an improved gross margin percentage in all five
        categories of IOLs year over year.
    --  Shipments of the nanoFLEX IOL have occurred for on-going trials with
        surgeons in two key European markets.  The pre-market launch of the
        newly approved nanoFLEX Toric IOLs are expected to begin during the
        second quarter, at which time, the Company will introduce both nanoFLEX
        models to additional European markets.

First Quarter Financial Highlights

    --  Total net sales in the first quarter increased 4%, or $0.7 million, to
        $15.5 million from $14.8 million in the first quarter of 2011.  Foreign
        currency transactions had a favorable impact on sales of $0.1 million
        which is $0.3 million less gain than the prior year first quarter
        impact.  Net sales were also affected by a $0.3 million, or 34%, decline
        in sales of the "other" product category on which the Company is not
        focused.
    --  Gross margin increased to a record 70.3% of revenue compared with 64.8%
        in the prior year's first quarter.  The increase reflected a higher mix
        of ICL to total sales of 56%, as compared to 46% during the first
        quarter of 2011, and a 200 basis point improvement in IOL margins.
    --  Total operating expenses were $10.6 million, a 13% increase over $9.4
        million in the first quarter of 2011.  Manufacturing consolidation
        expenses totaled $0.6 million during the quarter.  Excluding
        consolidation expenses, operating expenses were $10.1 million, a 8%
        increase over the 2011 first quarter.  The non-cash charge during the
        quarter for stock-based compensation increased by $332,000 despite the
        issuance of the same number of options, reflecting an increase in the
        Company's stock price from the prior year period.
    --  Other expenses contributed $186,000 versus $395,000 in the prior year
        period.  This was driven by the over $300,000 decrease in gains on
        foreign currency transactions offset to some degree by an increase in
        royalty income and a decrease in interest expense.
    --  GAAP net income in the first quarter of 2012 totaled $232,000, or $0.01
        per diluted share, compared with net income in the first quarter last
        year of $300,000, or $0.01 per diluted share.  Adjusted net income was
        $1.4 million, or $0.04 per diluted share, compared with adjusted net
        income during the first quarter of 2011 of $0.3 million, or $0.01 per
        diluted share.
    --  Cash and cash equivalents and restricted cash totaled $16.4 million at
        March 30, 2012 compared with $16.7 million at December 30, 2011 and
        $10.4 million at April 1, 2011.  The Company used $0.4 million in cash
        for operating activities during the first quarter due to expenditures
        associated with the manufacturing consolidation including an investment
        in inventories.  This investment in inventory is to help guarantee no
        disruption in customer supply during the transitions and $0.4 million in
        cash was used for this purpose during the quarter.

Second Quarter and Remainder of Year Key Events

    --  Continued penetration of the V4c ICL into the currently approved
        markets.  Penetration rate was 58% during first quarter.
    --  Expanding the approval of the V4c ICL to additional targeted markets
        outside of Europe.
    --  Release of nanoFLEX Toric IOL for pre-market launch to Europe which is
        planned during the second quarter of 2012.
    --  Complete the transfer of the enhanced KS-SP preloaded single piece
        acrylic from R&D to manufacturing in order to begin shipping this new
        product.
    --  With the completion of the R&D inventions for the V5 Preloaded ICL,
        complete the file for CE Mark and plan to gain additional surgeon input
        and support prior to the ESCRS meeting in Milan during September.

Conference Call

The Company will host a conference call and video webcast today, May 2, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's first quarter 2012 financial results and recent corporate developments. The dial-in number for the conference call is 877-941-9205 for domestic participants and 480-629-9771 for international participants.

The Company will also be using slides to illustrate its first quarter 2012 results and operational progress. The slides and live webcast of the call can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4531978#. An archived webcast will also be available at www.staar.com.

Use of Non-GAAP Financial Measures

This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. "Adjusted Net Income" excludes the following items that are included in "Net Income" as calculated in accordance with U.S. generally accepted accounting principles ("GAAP"): manufacturing consolidation expenses, gain or loss on foreign currency transactions, the fair value adjustment of outstanding warrants issued in 2007, and stock-based compensation expenses.

We believe that "Adjusted Net Income" is useful to investors in gauging the outcome of the key drivers of our business performance: our ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which we have control.

We have excluded manufacturing consolidation expenses because these are non-recurring expenses and their inclusion may mask underlying trends in our business performance.

We have excluded gains and losses on foreign currency transactions and the fair value adjustment of warrants because of the significant fluctuations that can result from period to period as a result of market driven factors.

Stock-based compensation expenses consist of expenses for stock options and restricted stock under Statement of Financial Accounting Standards ("SFAS") No. 123R. In calculating Adjusted Net Income STAAR excludes these expenses and the fair value adjustment of outstanding warrants because they are non-cash expenses and because of the complexity and considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.

We have provided below a detailed reconciliation table, which is useful to investors in providing the context to understand our Adjusted Net Income and how it differs from Net Income calculated in accordance with GAAP.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." Over 300,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 full time employees and markets lenses in approximately 50 countries. Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA. For more information, please visit the Company's website at www.staar.com or call 626-303-7902.

Collamer® is the registered trademark for STAAR's proprietary biocompatible collagen copolymer lens material.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: any projections of earnings, revenue, sales, profit margins, cash or any other financial items; the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; prospects for increased sales as a result of new product introductions or new product approvals, expected savings from business consolidation plans and the timetable for those plans; the approval of pending regulatory applications; statements of belief; and any statements of assumptions underlying any of the foregoing.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited capital resources and limited access to financing; the negative effect of poor global economic conditions on sales of products, especially products such as the ICL used in non-reimbursed elective procedures; the challenge of managing our foreign subsidiaries; backlog as we ramp up production to meet rapidly growing demand for our products; the risk of unfavorable changes in currency exchange rate; the discretion of regulatory agencies to approve or reject new products, or to require additional actions before approval; unexpected costs or delays that could reduce or eliminate the expected benefits of our consolidation plans; the risk that research and development efforts will not be successful or may be delayed in delivering for launch; the willingness of surgeons and patients to adopt a new product and procedure; patterns of Visian ICL use that have typically limited our penetration of the refractive surgery market, and a general decline in the demand for refractive surgery particularly in the U.S., which STAAR believes has resulted from both concerns about the safety and effectiveness of laser procedures and current economic conditions. The Visian Toric ICL and the V4c are not yet approved for sale in the United States.

    CONTACT: Investors          Media
             EVC Group          EVC Group
              Jenifer Kirtland,
              415-568-9349      Christopher Gale, 646-201-5431
              Douglas Sherk,
              415-652-9100

    STAAR Surgical Company
    Condensed Consolidated Balance Sheets
    (in 000's)


                                          March 30,          December 30
                                                       2012                  2011
                                                       ----                  ----
         ASSETS
    Current assets:
    Cash and cash equivalents                       $16,445               $16,582
    Restricted cash                                       -                   129
    Accounts receivable trade,
     net                                              8,331                 9,089
    Inventories, net                                 11,145                10,933
    Prepaids, deposits, and other
     current assets                                   2,583                 1,921
       Total current assets                          38,504                38,654
                                                     ------                ------
    Property, plant, and
     equipment, net                                   4,171                 4,222
    Intangible assets, net                            2,673                 2,989
    Goodwill                                          1,786                 1,786
    Deferred income taxes                               151                   152
    Other assets                                      1,135                 1,203
                                                      -----                 -----
       Total assets                                 $48,420               $49,006
                                                    =======               =======

         LIABILITIES AND STOCKHOLDERS'
          EQUITY
    Current liabilities:
    Line of credit                                   $2,420                $2,580
    Accounts payable                                  3,082                 4,261
    Deferred income taxes                               472                   472
    Obligations under capital
     leases                                             869                   597
    Other current liabilities                         5,661                 6,106
                                                      -----                 -----
       Total current liabilities                     12,504                14,016
                                                     ------                ------
    Obligations under capital
     leases                                             736                 1,124
    Deferred income taxes                               766                   708
    Other long-term liabilities                       3,691                 3,700
                                                      -----                 -----
    Total liabilities                                17,697                19,548
                                                     ------                ------


    Stockholders' equity:
    Common stock                                        362                   360
    Additional paid-in capital                      158,944               157,383
    Accumulated other
     comprehensive income                             1,875                 2,405
    Accumulated deficit                            (130,458)             (130,690)
                                                   --------              --------
       Total stockholders' equity                    30,723                29,458
                                                     ------                ------
    Total liabilities and
     stockholders' equity                           $48,420               $49,006
                                                    =======               =======

    STAAR Surgical Company
    Condensed Consolidated Statements of Operations
    (In 000's except for per share data)





                                                               Three Months Ended
                                                               ------------------
                                                    % of                March 30,         % of         April 1,          Change
                                                                                                                         ------
                                                    Sales                           2012  Sales                    2011  Amount         %
                                                                                    ----                           ----  ------        ---

    Net sales                                             100.0%                 $15,509        100.0%          $14,849          $660        4.4%

    Cost of sales                                          29.7%                   4,607         35.2%            5,220           613      -11.7%
                                                                                   -----                          -----           ---

    Gross profit                                           70.3%                  10,902         64.8%            9,629         1,273       13.2%
                                                                                  ------                          -----         -----

    Selling, general
     and administrative
     expenses:
      General and
       administrative                                      24.8%                   3,860         22.9%            3,397           463       13.6%
      Marketing and
       selling                                             30.1%                   4,663         30.0%            4,459           204        4.6%
      Research and
       development                                         10.0%                   1,546          9.6%            1,432           114        8.0%
                                                                                   -----                          -----           ---
         Selling, general,
          and administrative
          expenses                                         64.9%                  10,069         62.5%            9,288           781        8.4%
      Other general and
       administrative
       expenses                                             3.6%                     555          0.9%              133           422        0.0%
                                                                                     ---                            ---           ---

         Total selling,
          general and
          administrative
          expenses                                         68.5%                  10,624         63.4%            9,421         1,203       12.8%
                                                                                  ------                          -----         -----

    Operating income                                        1.8%                     278          1.4%              208            70       33.7%
                                                                                     ---                            ---           ---

    Other income
     (expense):
      Interest income                                       0.0%                       0          0.1%               13           (13)     -99.2%
      Interest expense                                     -0.6%                     (95)        -1.0%             (153)           58      -37.9%
      Gain on foreign
       currency
       transactions                                         0.4%                      67          2.5%              372          (305)     -82.0%
      Other income, net                                     1.4%                     214          1.1%              163            51       31.3%
                                                                                     ---                            ---           ---
        Total other income                                  1.2%                     186          2.7%              395          (209)     -52.9%
                                                                                     ---                            ---          ----

    Income before
     provision for
     income taxes                                           3.0%                     464          4.1%              603          (139)     -23.0%

    Provision for
     income taxes                                           1.5%                     232          2.1%              303           (71)     -23.4%
                                                                                     ---                            ---           ---

    Net income                                              1.5%                    $232          2.0%             $300          $(68)     -22.6%
                                                                                    ====                           ====          ====



    Net Income per
     share-basic                                                                   $0.01                          $0.01
                                                                                   =====                          =====
    Net Income per
     share-diluted                                                                 $0.01                          $0.01
                                                                                   =====                          =====

    Weighted average
     shares outstanding
     -basic                                                                       36,071                         35,188
                                                                                  ======                         ======
    Weighted average
     shares outstanding
     -diluted                                                                     38,420                         36,389
                                                                                  ======                         ======

    STAAR Surgical Company
    Condensed Consolidated Statements of Cash Flows
    (in 000's)

                                                                                     Year Ended
                                                                                     ----------
                                                                         March 30,         April 1,
                                                                                     2012             2011
                                                                                     ----             ----
    Cash flows from operating
     activities:
       Net income                                                             $232             $300
       Adjustments to reconcile
        net income to net cash
        (used in) provided by
        operating activities:
                                     Depreciation of property and
                                     equipment                                        317              307
                                    Amortization of intangibles                       175              197
                                    Deferred income taxes                              57               44
                                    Fair value adjustment of warrant                   14             (103)
                                    Change in net pension liability                    72               60
                                     Gain on disposal of property and
                                     equipment                                          -              (14)
                                    Stock-based compensation expense                  687              355
                                    Other                                              40              (81)
       Changes in working capital:
                                    Accounts receivable, net                          556              666
                                    Inventories                                      (432)             548
                                     Prepaids, deposits and other
                                     current assets                                  (665)            (473)
                                    Accounts payable                               (1,100)             (87)
                                    Other current liabilities                        (390)          (1,169)
                                          Net cash (used in) provided by
                                           operating activities                      (437)             550


    Cash flows from investing
     activities:
                                     Acquisition of property and
                                     equipment                                       (287)             (44)
                                    Release of restricted cash                        129                -
                                     Proceeds from the sale of property
                                     and equipment                                      -               26
                                    Net change in other assets                          -               48
                                          Net cash (used in) provided by
                                           investing activities                      (158)              30


    Cash flows from financing
     activities:
                                     Repayment of capital lease lines
                                     of credit                                       (195)            (131)
                                     Proceeds from the exercise of
                                     stock options                                    837              606
                                          Net cash provided by financing
                                           activities                                 642              475


    Effect of exchange rate
     changes on cash and cash
     equivalents                                                                     (184)            (219)
                                                                                     ----             ----

    (Decrease) increase in cash
     and cash equivalents                                                            (137)             836
    Cash and cash equivalents,
     at beginning of year                                                          16,582            9,376
    Cash and cash equivalents,
     at end of year                                                        $16,445          $10,212
                                                                           =======          =======

    STAAR Surgical Company
    Global Sales
    (in 000's)



                           Three Months Ended
                           ------------------
                                          March 30,                April 1,            %
     Geographic
     Sales                                             2012                    2011 Change
                                                       ----                    ---- ------
     United
     States                 20.5%                    $3,174  23.8%           $3,533        -10.2%

    Japan                   24.9%                     3,857  25.9%            3,845          0.3%
    Korea                   12.3%                     1,903   9.3%            1,384         37.5%
    China                   13.6%                     2,106   8.1%            1,204         74.9%
    Other                   28.7%                     4,469  32.9%            4,883         -8.5%
                                                      -----                   -----
       Total
       International
       Sales                79.5%                    12,335  76.2%           11,316          9.0%

         Total
         Sales             100.0%                   $15,509 100.0%          $14,849          4.4%
                                                    =======                 =======


     Product
     Sales
       Core
       products
        ICLs                55.5%                    $8,605  46.4%           $6,897         24.8%
        IOLs                41.0%                     6,358  48.0%            7,120        -10.7%
       Total
       core
       products             96.5%                    14,963  94.4%           14,017          6.7%
                                                     ------                  ------
       Non-
       core
       products
        Other                3.5%                       546   5.6%              832        -34.4%
                                                        ---                     ---
         Total
         Sales             100.0%                   $15,509 100.0%          $14,849          4.4%
                                                    =======                 =======

    STAAR Surgical Company
    Reconciliation of Non-GAAP Financial Measure

                                                      Three Months
                                                          Ended
                                                     -------------
                                                       March 30,        April 1,
                                                                  2012            2011
                                                                  ----            ----
    Net income -(as
     reported)                                                    $232            $300
    Less:
      Manufacturing
       consolidation
       expenses                                                    555             133
      Gain on foreign
       currency                                                    (67)           (372)
      Fair value adjustment
       of warrants                                                  14            (103)
      Stock-based
       compensation expense                                        687             355
    Net income  -
     (adjusted)                                                 $1,421            $313
                                                                ======            ====

    Net income per share,
     basic -(as reported)                                        $0.01           $0.01
      Manufacturing
       consolidation
       expenses                                                  $0.02           $0.00
      Gain on foreign
       currency                                                 $(0.00)         $(0.01)
      Fair value adjustment
       of warrants                                               $0.00          $(0.00)
      Stock-based
       compensation expense                                      $0.02           $0.01
    Net income per share,
     basic -(adjusted)                                           $0.04           $0.01
                                                                 =====           =====

    Net income per share,
     diluted -(as
     reported)                                                   $0.01           $0.01
      Manufacturing
       consolidation
       expenses                                                  $0.01           $0.00
      Gain on foreign
       currency                                                 $(0.00)         $(0.01)
      Fair value adjustment
       of warrants                                               $0.00          $(0.00)
      Stock-based
       compensation expense                                      $0.02           $0.01
    Net income per share,
     diluted -(adjusted)                                         $0.04           $0.01
                                                                 =====           =====

    Weighted average
     shares outstanding -
     Basic                                                      36,071          35,188
    Weighted average
     shares outstanding -
     Diluted                                                    38,420          36,389

    Note:  Net income per share (adjusted), basic and diluted, may
     not add up due to rounding

SOURCE STAAR Surgical Company

Copyright (2014) PR Newswire. All Rights Reserved.
Back to STAA
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki